Cost-effectiveness of peginterferon alfa-2a (40KD) (PEGASYS®) compared to lamivudine as first line treatment of chronic hepatitis B (CHB) in the UK

被引：0
|
作者：
Veenstra, DL
Sullivan, SD
Dusheiko, GM
Jacobs, M
Lewis, GJ
Patel, KK
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Royal Free Hampstead NHS Trust, London, England
[3] Roche Prod Ltd, Welwyn Garden City AL7 3AY, Herts, England
[4] Hoffmann La Roche Inc, Nutley, NJ 07110 USA
来源：
VALUE IN HEALTH | 2005年 / 8卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A120 / A120
页数：1
相关论文
共 50 条
  • [41] Histologic benefit of peginterferon alfa-2a (40kd) (Pegasys®) monotherapy in patients with advanced fibrosis or cirrhosis due to chronic hepatitis C.
    Everson, G
    Heathcote, J
    Pappas, SC
    Govindarajan, S
    Lentz, E
    Lopez-Talavera, JC
    HEPATOLOGY, 2004, 40 (04) : 316A - 316A
  • [42] Factors associated with sustained virologic response 1 year after treatment with peginterferon alfa-2A (40KD) (PEGASYS®) monotherapy for HBEAG-negative chronic hepatitis B
    Marcellin, P
    Bonino, F
    Lau, GY
    Farci, P
    Yurdaydin, C
    Piratvisuth, T
    Jin, R
    Gurel, S
    Hadziyannis, S
    Lu, ZM
    Popescu, M
    HEPATOLOGY, 2005, 42 (04) : 580A - 580A
  • [43] Predicting response to peginterferon alfa-2a (40 KD) (PEGASYS®) in Asian patients with HBeAg-positive chronic hepatitis B
    Cooksley, Graham
    Chow, Wan Cheng
    Piratvisuth, Teerha
    Lau, George K. K.
    Mccloud, Philip
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A108 - A108
  • [44] Role of baseline and on-treatment quantitative HBeAg in predicting response to peginterferon alfa-2a (40KD) (PEGASYS®) monotherapy in a large, multinational trial of patients with chronic hepatitis B
    Fried, MW
    Liaw, YF
    Luo, KX
    Lau, GK
    Piratvisuth, T
    Cooksley, G
    Marcellin, P
    Thongsawat, S
    Mai, C
    Flisiak, R
    McCloud, P
    Why, D
    Pluck, N
    HEPATOLOGY, 2005, 42 (04) : 268A - 268A
  • [45] Efficacy and Safety of Peginterferon Alfa-2a (40KD) in Children With Chronic Hepatitis B: The PEG-B-ACTIVE Study
    Wirth, Stefan
    Zhang, Hongfei
    Hardikar, Winita
    Schwarz, Kathleen B.
    Sokal, Etienne
    Yang, Weibo
    Fan, Huimin
    Morozov, Vyacheslav
    Mao, Qing
    Deng, Hong
    Huang, Yang
    Yang, Lei
    Frey, Nicolas
    Nasmyth-Miller, Clare
    Pavlovic, Vedran
    Wat, Cynthia
    HEPATOLOGY, 2018, 68 (05) : 1681 - 1694
  • [46] PREDICTIVE FACTORS OF THROMBOCYTOPENIA IN TREATMENT OF CHRONIC HEPATITIS C (CHC) PATIENTS WITH PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN
    Mauss, S.
    Schober, A.
    Lutz, T.
    Moog, G.
    Schuchmann, M.
    Heyne, R.
    John, C.
    Schiffelholz, W.
    Baumgarten, A.
    Hey, K. -H.
    Eisenbach, C.
    Teuber, G.
    Schmidt, W.
    Bruch, H. -R.
    Geyer, P.
    Alshuth, U.
    Hueppe, D.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S185 - S185
  • [47] Efficacy and safety of 22 weeks of maintenance therapy with Peginterferon alfa-2a (40KD) (PEGASYS™) alone versus Peginterferon alfa-2a (40KD) plus ribavirin(COPEGUS™) in naive patients with chronic hepatitis C and genotype 1 who responded to a 24-week course of Peginterferon alfa-2a (40KD) plus ribavirin:: An open, multicenter, randomized trial.
    Bronowicki, JP
    Ouzan, D
    Tzanck, A
    Asselah, T
    Desmorat, H
    Zarski, JP
    Foucher, J
    Bourliere, M
    Renou, C
    Tran, A
    Melin, P
    Hezode, C
    Chevallier, M
    Bouvier, M
    Lonjon-Domanec, I
    Pawlotsky, JM
    HEPATOLOGY, 2003, 38 (04) : 244A - 245A
  • [48] Predictive Factors of Thrombocytopenia in Treatment of Chronic Hepatitis C (CHC) Patients With Peginterferon Alfa-2a (40KD) and Ribavirin
    Mauss, Stefan
    Schober, Andreas
    Lutz, Thomas
    Moog, Gero
    Schuchmann, Marcus
    Heyne, Renate
    John, Christine
    Schiffelholz, Willibold
    Baumgarten, Axel
    Hey, Karl-Heinz
    Eisenbach, Christoph
    Teuber, Gerlinde
    Schmidt, Wolfgang
    Bruch, Harald-Robert
    Geyer, Peter
    Alshuth, Ulrich
    Hueppe, Dietrich
    GASTROENTEROLOGY, 2011, 140 (05) : S948 - S948
  • [49] Effect of ethnicity, genotype, gender, age and bodyweight on sustained response in a large, randomised study of peginterferon alfa-2A (40KD) (PEGASYS®) +/- lamivudine versus lamivudine alone for HBEAG-positive chronic hepatitis B
    Chow, WC
    Manns, M
    Paik, SW
    Berg, T
    Piratvisuth, T
    Chang, WY
    Lau, GK
    Marcellin, P
    Gane, E
    Pluck, N
    HEPATOLOGY, 2005, 42 (04) : 576A - 576A
  • [50] Cost-effectiveness of treating adults with chronic hepatitis C (CHC) and persistently normal alanine aminotransferase (PNALT) with peginterferon alfa-2a (40 kD) (Pegasys) plus ribavirin (Copegus)
    Hornberger, J
    Farci, P
    Prati, D
    Zuezem, S
    Patel, KK
    Green, J
    VALUE IN HEALTH, 2004, 7 (03) : 347 - 348
12345